Loading clinical trials...
Loading clinical trials...
A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment
Conditions
Interventions
ganaxolone
Placebo
Locations
71
United States
University of Alabama Epilepsy Center
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Xenoscience Inc.
Phoenix, Arizona, United States
The MORE Foundation
Sun City, Arizona, United States
Clinical Trials Inc.
Little Rock, Arkansas, United States
Neuro-Pain Medical Center, Inc
Fresno, California, United States
Start Date
October 1, 2013
Primary Completion Date
May 1, 2016
Completion Date
October 1, 2016
Last Updated
February 14, 2023
Lead Sponsor
Marinus Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions